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doi:10.1016/j.hkjn.2012.01.001Summary Background/Purpose: Several types of herbal preparations have been used as
supplementary therapies for the treatment of progressive chronic kidney disease (CKD), but
the scientific evidence for their use is scarce. The aim of the present study was to determine
the effects of Astragalus membranaceus on renal outcome in patients with progressive CKD.
Methods and Results: The study population consisted of 35 patients with CKD stages 4 and 5
whose estimated glomerular filtration rate (eGFR) decreased over a 3-month period before
the start of A membranaceus treatment despite the use of conventional therapy (from
14.6  6.28 mL/min/1.73 m2 to 11.6  5.24; mean  SD, p< 0.05). Similarly, the eGFR of 15
patients with CKD stage 4 decreased over the same period despite conventional therapy (from
20.8  4.59 to 16.7  4.17; rZ 1.298; p< 0.05), but increased after the initial period of 3
months of supplementary treatment with A membranaceus (to 18.6  5.67; rZ 0.973;
p< 0.05) and remained at that level at 6 months (17.8  5.60) and 12 months (16.3  5.89).
However, in 20 patients with CKD stage 5, the beneficial effect of A membranaceus was limited
to the first 3 months only (3 months: 10.5 2.7, baseline: 8.0 2.75, 3 months: 8.4 2.96, 6
months: 6.8 2.45).Amembranaceus had no significant effects on other laboratory parameters.
Only seven patients (1 in stage 4 and 6 in stage 5) required dialysis within 12 months of A mem-
branaceus treatment, whose eGFR at baseline was relatively low (7.4 1.06).
Conclusion: The results suggest that A membranaceus can maintain stable levels of eGFR and
delay the initiation of renal replacement therapy in patients with progressive CKD stage 4.
至今已有數種草藥製劑被應用於進行性慢性腎病(CKD)的補充療法，然而此用途仍缺乏相關的科學
理據。本研究旨在探討膜莢黃耆(Astragalus membranaceus)對進行性CKD患者的腎臟效應。研究
對象為35位第4或5期CKD患者，即使在常規治療下(不包括A membranaceus)，其腎絲球過濾率估ephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, 2-1-1 Hongo,
.jp (Y. Tomino).
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18 M. Okuda et al.算值(eGFR)仍在3個月內明顯下降(從14.6  6.28 mL/min/1.73 m2至11.6  5.24; mean  SD,
p< 0.05)。其中15人為第4期CKD患者，eGFR於該段期間明顯下降(從20.8 4.59至16.7 4.17;
rZ 1.298; p < 0.05)，但在膜莢黃耆補充療法開始後3個月回升(至18.6  5.67; rZ 0.973;
p< 0.05)，並維持穩定於6個月(17.8 5.60)及12個月(16.3 5.89)。另外20位為第5期CKD患者，
膜莢黃耆對其效益僅可見於首3個月(3個月: 10.5 2.7,基線: 8.0 2.75, 3個月: 8.4 2.96, 6個
月: 6.8  2.45)。至於其他實驗室項目，膜莢黃耆並不具明顯效應。在膜莢黃耆的12個月治療期
間，僅7人(第4期：1人；第5期：6人)需接受透析治療，其基線eGFR均偏低(7.4 1.06)。因此，對
於第4期進行性CKD患者，膜莢黃耆有助維持eGFR於穩定水平，並延遲腎臟替代療法的開始時間.for 3 months, and their data were excluded from the anal-Introduction
With increasing numbers of patients undergoing renal
replacement therapy, the cost of chronic kidney disease
(CKD) is rising worldwide.1 The number of patients requiring
dialysis therapy in Japan has also increased almost linearly,
about 10,000 a year, since surveys began in 1983, reaching
297,126 at the end of 2010. Therefore, it is important to
establish strategies to delay the progression to end-stage
kidney disease in CKD patients. However, despite signifi-
cant advances in conventional medicine, no specific treat-
ment is available for patients with stages 4 and 5 CKD. There
is definitely a need for the use of combinations of different
treatment modalities to control the progression of CKD,
highlighting the importance of research on discovering new
pharmacological agents for CKD.2 In Japan, not only tradi-
tional herbalists but also nephrologists have occasionally
used herbal medicine for treatment of patients with CKD,
including some imported from China, as part of combination
therapy.3 Traditional herbalists usually prescribe a blend of
several herbs such as Astragalus membranaceus, Angelica
sinensis, Angelica acutiloba, Salvia miltiorrhiza, and
rhubarb to patients with renal disease. Among these herbal
medicines, formulations containing A membranaceus have
often been used for renal disorders based on their diuretic
action and reduction of proteinuria.4,5 In addition, A mem-
branaceus is believed to have beneficial effects on other
conditions such as diabetesmellitus6,7 and cardiovascular,8,9
digestive,10,11 hepatic,12 neurological,13,14 and allergic
diseases.15 Several recent experimental studies using animal
models of diabetic nephropathy6 and unilateral ureteral
obstruction (UUO) renal fibrosis16 have highlighted the
potency of A membranaceus. To our knowledge, however,
there are only a few clinical case reports in the English
literature on the effects of A membranaceus when used
alone for membranous nephropathy.17,18
The objective of our prospective study was to assess the
efficacy of A membranaceus in progressive CKD when used
in combination with conventional therapy. As it is not
randomized, we set up the primary endpoint to decline rate
of eGFR before and after treatment with A membranaceus.
Since several species of herbs are usually prescribed in
combination, the present study is the first clinical trial on
the use of A membranaceus alone.
Patients and methods
Patients
Of the 41 patients who were initially enrolled in this study,
sixwere unable to continue treatmentwithAmembranaceusysis. The reasons for cessation of treatment were revocation
of consent (nZ 3), start of dialysis therapy (nZ 1), diarrhea
(nZ 1), and change of hospital (nZ 1). Therefore, the study
population eventually consisted of 35 patients (15 with CKD
stage 4 and 20 with CKD stage 5) who were treated with A
membranaceus daily for more than 3 months.
Study design
Outpatients with progressive CKD stage 4 to 5 who consented
to undergo treatment with A membranaceus were enrolled
in this study. Progressive CKD in this study was defined as
reduction in the estimated glomerular filtration rate (eGFR)
over a period of 3 months preceding enrollment in the study
despite the use of conventional therapy. We compared the
slope of eGFR decline before and after treatment with A
membranaceus. All enrolled patients were already being
treated for CKD-related complications such as hypertension,
renal anemia, metabolic acidosis, and mineral bone disease
with antihypertensive drugs, erythropoietin, xanthine
oxidase inhibitors, sodium bicarbonate, vitamin D analogs,
and absorbant AST120.19 During the study, the patients were
advised to continue to take all their medications wherever
possible. The trial protocol was approved by the institutional
review board of Juntendo University Hospital, and all
patients gave written informed consent. Whenever a patient
demanded a revocation of consent, we excluded that
patient’s information from our study.
TheAmembranaceus used in this studywas inspected and
certified according to the regulations established by the
Japanese Pharmacopeia. Participants were treated with
2.5 g A membranaceus twice a day, together with conven-
tional therapy. There was no prohibited combination of
drugs. The primary outcome measurement was retardation
of CKD progression as assessed by the slope of eGFR. The
eGFR for each patient was estimated using the four-variable
Modifications of Diet in Renal Disease study equation.20
The following information was recorded every 4 weeks
at each visit to Juntedo University Hospital: body weight,
blood pressure, hemoglobin (Hb), serum creatinine, blood
urea nitrogen (BUN), uric acid (UA), Na, K, Cl, albumin, low-
density lipoprotein cholesterol, e-GFR, and urinary protein
excretion (mg/g∙Cr).
Statistical analyses
Data are expressed as mean SD. Statistical comparison of
data before and after treatment with A membranaceus was
performed using the ManneWhitney U-test, and the anal-
ysis of changes in eGFR was performed using the paired
Table 1 Clinical characteristics of the patients.
All patients (nZ 35) CKD stage 4 (nZ 15) CKD stage 5 (nZ 20)
Age (y) 64.1 13.1 62.4 15.7 66.8 12.6
Females/males 22/13 9/6 13/7
Body weight (kg) 62.4 11.9 61.2 11.4 64.6 12.9
Body mass index (kg/m2) 24.0 3.9 23.3 4.0 24.5 3.8
Systolic blood pressure (mmHg) 130.5 16.4 129.9 17.3 131.2 18.3
Diastolic blood pressure (mmHg) 75.3 9.6 75.0 13.2 78.2 10.2
eGFR (mL/min/1.73 m2) 11.69 5.49 16.74 4.17 8.03 2.69
Treatment (%)
ACEI or ARB 65.7 66.7 65.0
Vitamin D analog 14.3 6.7 20.0
Sodium bicarbonate 28.6 13.3 40.0
Diuretics 31.4 46.7 20.0
Primary disease Hypertensive nephrosclerosis nZ 13
Chronic glomerulonephritis nZ 10
Diabetic nephropathy nZ 5
Polycystic kidney disease nZ 4
Chronic interstitial nephritis nZ 2
Vesicoureteral reflux nZ 1
Data are mean SD or number of patients.
ACEI Z angiotensin converting enzyme inhibitor; ARDZ angiotensin II receptor blocker; CKDZ chronic kidney disease; eGFRZ esti-
mated glomerular filtration rate.
Beneficial effects of Astragalus membranaceus in CKD patients 19t-test (StatView version 5.0; SAS Institute Inc., Tokyo,
Japan). A p value <0.05 was considered statistically signif-
icant. The correlation coefficient between before and after
treatment with A membranaceus was expressed as rZ .
Results
Demographic and clinical characteristics
of the patients
In these patients, the primary kidney diseases were neph-
rosclerosis (nZ 13), chronic glomerulonephritis (nZ 10),Table 2 Serial changes in various clinical and laboratory par
membranaceus in the entire patients populations.
3 mo 0 mo
n 35 35
Systolic blood pressure (mmHg) 135 15.0 131 16.4
Diastolic blood pressure (mmHg) 77 10.1 75 9.6
Hemoglobin (g/dL) 10.9 1.6 11.0 1.5
BUN (mg/dL) 47.4 18.6 48.7 18.1
Serum creatinine (mg/dL) 3.87 1.65 4.03 1.73
eGFR (mL/min/1.73 m2) 14.56 6.28 11.55 5.24*
Uric acid (mg/dL) 7.26 1.49 7.51 1.41
Albumin (g/dL) 3.89 0.43 3.92 0.46
LDL-C (mg/dL) 100.5 25.2 102.5 25.1
Na (mmol/L) 140.4 2.2 139.6 3.3
K (mmol/L) 4.8 0.5 4.8 0.6
Cl (mmol/L) 106.5 3.5 106.8 4.5
Proteinuria (g/g∙Cr) 2.44 2.39 1.87 1.83
Data are mean SD.
*p< 0.05, compared with the value at 3 months. For abbreviations,
BUNZ blood urea nitrogen; LDL-CZ low-density lipoprotein cholestediabetic nephropathy (nZ 5), autosomal dominant poly-
cystic kidney disease (nZ 4), chronic interstitial nephritis
(nZ 2), and vesicoureteral reflux (nZ 1). This group con-
sisted of 22 (63%) males and 13 (47%) females aged 40e94
years (64.1 13.1). Table 1 lists the demographic and
clinical characteristics, blood pressure, laboratory findings,
and drug usage of these patients.
Changes in eGFR and proteinuria
For the entire group of 35 patients, the mean eGFR at
3 months before the administration of A membranaceusameters during combination treatment including Astragalus
3 mo 6 mo 9 mo 12 mo
35 26 20 16
136 17.5 133 17.1 128 12.5 126 13.0
76 8.7 76 7.9 76 8.5 75 9.1
10.8 1.4 10.6 1.6 10.2 2.4 10.6 1.3
54.2 23.1 52.0 23.4 43.4 17.8 47.6 14.1
3.87 1.88 3.63 1.65 3.30 1.47 3.29 1.40
12.81 6.68 13.54 6.65 14.42 6.45 13.89 6.09
7.79 1.65 7.21 1.43 7.28 1.10 7.81 0.90
3.97 0.82 3.86 0.56 3.81 0.52 3.86 0.48
99.5 29.8 94.5 34.3 91.6 26.5 89.8 24.0
139.8 2.7 140.7 1.7 139.8 2.1 139.7 2.9
4.7 0.5 4.7 0.5 5.0 0.5 4.9 0.6
106.6 3.9 107.1 2.7 106.8 3.2 106.5 4.4
2.14 2.17 3.08 4.71 4.38 5.97 1.38 1.29
see Table 1.
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20 M. Okuda et al.was 14.6 6.3 mL/min/1.73 m2 and decreased even with
conventional therapy to 11.6 5.2 mL/min/1.73 m2 at
study enrollment (rZ1.232, pZ 0.0026). The eGFR
recovered to 12.8 6.7 mL/min/1.73 m2 after 3 months of
treatment (rZ 0.896), although BUN and UA tended to
increase slightly. We could measure 24-hour creatinine
clearance in 13 patients. A membranaceus also improved
creatinine clearance in the same way as eGFR
(3 M; 13.2 4.1 mL/min, 0 M; 9.4 2.9 mL/min, þ3 M;
10.5 4.1 mL/min, þ6 M: 9.8 4.3 mL/min, respectively)
in these patients. Other laboratory data remained
unchanged throughout the study (Table 2). Among the 35
patients, CKD was classified as stage 4 in 15. The eGFR at
baseline in this group was 20.8 4.6 mL/min/1.73 m2,
which decreased to 16.7 4.2 at baseline despite
conventional therapy (rZ1.329, p< 0.05). However,
after 3 months of treatment that included A mem-
branaceus, the eGFR increased to 18.6 5.7 mL/min/
1.73 m2 (rZ 0.973) and remained stable for the next 12
months (16.3 5.9 mL/min/1.73 m2) (Table 3). This effect
was not noted in 20 patients with CKD stage 5, with the
exception of a small increment in eGFR at 3 months (Table
3). No changes in BUN, hemoglobin, total protein,
albumin, low-density lipoprotein cholesterol, UA, and
urinary protein excretion were noted during the entire
study in the two groups (Table 3). There were also no
differences in primary disease, age, and sex between the
two groups. During this study, seven patients underwent
renal replacement therapy within 12 months of A mem-
branaceus treatment. Their eGFR at baseline was signifi-
cantly low (7.4 1.1 mL/min/1.73 m2) (Table 4). On the
other hand, 16 patients who continued A membranaceus
treatment for more than 12 months had a relatively high
eGFR at baseline (14.2 5.4 mL/min/1.73 m2). Further-
more, 13 patients with CKD stage 4 who continued A
membranaceus treatment for more than 24 months,
showed eGFR at 24 months of 13.3 5.24 mL/min/1.73 m2
and thus required no dialysis therapy. Unfortunately, we
could not follow up two patients who changed hospitals at
6e12 months.
The clinical courses of eGFR in each patient of 3 months
before to 3 months after treatment with A membranaceus
are shown in Fig. 1A. Although they already underwent
treatment with conventional therapy, the slope of eGFR
started to decline (rZ1.232) even before treatment.
After A membranaceus treatment for 3 months, the slope of
eGFR was significantly improved (rZ 0.896). However, this
effect did not continue after 6 months. The mean values of
eGFR of 3 months before to 12 months after treatment with
A membranaceus are shown in Fig. 1B. The improved eGFR
reverted to the level of 3 months after the treatment, for
6 months. The amount of proteinuria tended to decrease
after treatment with A membranaceus for 3 months, but it
was not statistically significant. On the other hand, incre-
ment of eGFR and decrement of proteinuria for 3 months
were well correlated (rZ 0.802, Fig. 1C).Adverse events
Twelve adverse events in 10 patients were reported. They
included skin eruptions (nZ 5, 12.2%), digestive symptoms
Table 4 Serial changes in serum creatinine and estimated glomerular filtration rate (eGFR) in seven patients who underwent
renal dialysis within 12 months of combination treatment including Astragalus membranaceus.
3 mo 0 mo 3 mo 6 mo
n 7 7 7 6
Creatinine (mg/dL) 4.75 0.72 5.28 0.75 5.17 0.75 5.84 1.16
eGFR (mL/min/1.73 m2) 10.78 1.27 7.42 1.06 7.45 1.82 6.61 1.82
Data are mean SD.
Beneficial effects of Astragalus membranaceus in CKD patients 21(nZ 3, 7.3%), anemia (nZ 2, 4.9%), and stomatitis (nZ 2,
4.9%). All events were mild to moderate in severity. Two
patients discontinued A membranaceus treatment tempo-
rarily due to skin rashes on the legs and gastritis, but they
resumed and continued treatment without any further
adverse events, suggesting that these adverse events were
rather associated with the uremic state.
Discussion
Since there are no specific therapies for recovery of renal
function after reaching the end stage of CKD, multidisci-
plinary treatment and diet therapy including protein
restriction are considered to delay the progression of CKD.2
In Japan, not only herbalists but general practitioners also
sometimes use Chinese herbal preparations as comple-
mentary therapies to reduce the rate of progression of CKD.
In general and traditional medicine, the prescribed herbs
are often polyherbal formulas, because it is generally
believed that herbs have synergistic effects. Among several
herbs, A membranaceus is often present in polyherbal
formulas prescribed for renal diseases because of its anti-
inflammatory and diuretic actions. For this reason, we
chose A membranaceus to study the effects of a single
herbal therapy in patients with CKD stages 4 and 5 whose
eGFR was decreasing in the previous 3 months, in place of
a multidisciplinary therapy. Since A membranaceus has
been inspected and certified by the Japanese government
health authorities and included in the health insurance
system, the cost of treatment is less than that with other
medicines such as oral adsorbent AST120,19 which is
sometimes used for the same purpose.
In this study, A membranaceus significantly increased
eGFR in patients with progressive CKD stage 4, but the
effectivity period was limited to about 1 year, because
otherwise A membranaceus might prolong the initiation of
renal replacement therapy for at least 1 year.
Progressive CKD was defined as a reduction in the eGFR
value over a period of 3 months preceding enrollment in this
study despite conventional therapy. We classified the stage
of CKD by eGFR at the start of A membranaceus treatment.
What is the underlying mechanism(s) of action of A
membranaceus on renal function? Previous studies repor-
ted that the combination of two herbs, A membranaceus
and Angelica sinensis, increased the densities of amino-
peptidase P-positive glomerular and peritubular capil-
laries, similar to enalapril treatment in five of six
nephrectomized rats.21 The authors concluded that up-
regulation of renal cortical vascular endothelial growth
factor in the treatment group reduced capillary loss andimproved microstructural dysfunction.21 In another study,
the same herbal combination also enhanced nitric oxide
production via activation of endothelial NO synthase and
scavenging reactive oxygen species in a mouse UUO
model.22 Based on a histopathological examination, the
enhanced production of NO was considered to explain the
improvement observed in ischemic microvasculature and
attenuation of interstitial fibrosis.22 Since A membranaceus
contains a relatively high amount of flavonoids which have
strong antioxidative action, it may exert these positive
effects on eGFR. In another study using the rat UUO model,
treatment with A membranaceus reduced the mRNA
expression levels of TGF-b1 and smooth muscle actin,
which rectified the decrease in fibronectin and type I
collagen depositions, suggesting that the renoprotective
effects of the two herbal medicines might be related to
inhibition of myofibroblast action.16 Motomura et al23
demonstrated that astragalosides, especially astragalo-
side V isolated from the root of Astragalus radix, inhibited
the formation of advanced glycation end products
(including both N-carboxymethyl-lysine and pentosidine)
in vitro. In rats with streptozotocin-induced diabetes,
treatment with A membranaceus improved renal function
by reducing nuclear factor-kappa B and increasing IkB
mRNA levels in the renal cortex.24 Although we could not
investigate the mechanisms of action of A membranaceus
in our clinical study, the results confirmed that A mem-
branaceus was able to maintain the eGFR during the study
period. The effects of A membranaceus were similar
regardless of the underlying mechanism of CKD. The
significant temporal increment of eGFR was not recognized
in patients with CKD stage 5, suggesting that the number of
residual nephrons is critical for the effect of A mem-
branaceus. The beneficial effects of A membranaceus
allowed a delay in the initiation of renal replacement
therapy in patients with progressive CKD stage 4. Hence,
early commencement of A membranaceus treatment might
enhance the beneficial effects with a clearer impact on
the disease process. The reason why A membranaceus
improved eGFR but had no effect on BUN and UA was not
clear. Since most patients took loop diuretics, the effect of
diuretics may be one of the reasons.
Several adverse events of A membranaceus were
observed within the first month of treatment. However,
these side effects were mild, and recovery was noted
following discontinuation of the herbal preparation.
Accordingly, daily treatment with A membranaceus for up
to 24 months seems to be safe.
In conclusion, A membranaceus should be effective in
the treatment of progressive CKD, but a randomized control
Figure 1 (A) Estimated glomerular filtration rate (eGFR)-time plot for 35 patients 3 months before, at the start of, and 3 months
after treatment with Astralagalus membranaceus. (B) The mean eGFR values of patients from 3 months before to 12 months after
treatment with A membranaceus. Asterisk indicates significance (<0.05) compared with the value at 3 months before treatment
with A membranaceus. (C) Proteonuria-time plot for patients from 3 months before to 12 months after treatment with A
membranaceus.
22 M. Okuda et al.
Beneficial effects of Astragalus membranaceus in CKD patients 23study is needed to confirm the exact effects of this herbal
preparation.
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